Anil Potti
#121,765
Most Influential Person Now
Cancer scientist accused of misconduct and fraud
Anil Potti's AcademicInfluence.com Rankings
Anil Pottiphilosophy Degrees
Philosophy
#11442
World Rank
#15755
Historical Rank
#2185
USA Rank
Logic
#8519
World Rank
#10677
Historical Rank
#1415
USA Rank
Download Badge
Philosophy Biology
Why Is Anil Potti Influential?
(Suggest an Edit or Addition)According to Wikipedia, Anil Potti is a physician and former Duke University associate professor and cancer researcher, focusing on oncogenomics. He, along with Joseph Nevins, are at the center of a research fabrication scandal at Duke University. On 9 November 2015, the Office of Research Integrity found that Potti had engaged in research misconduct. According to Potti's voluntary settlement agreement with ORI, Potti can continue to perform research with the requirement of supervision until year 2020, while he "neither admits nor denies ORI's findings of research misconduct." As of 2020 Potti, who is employed at the Cancer Center of North Dakota, has had 11 of his research publications retracted, one publication has received an expression of concern, and two others have been corrected.
Anil Potti's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Oncogenic pathway signatures in human cancers as a guide to targeted therapies (2006) (1992)
- Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. (2008) (807)
- A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. (2006) (599)
- Genomic signatures to guide the use of chemotherapeutics (2006) (397)
- A pathway-based classification of human breast cancer (2010) (307)
- Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. (2004) (296)
- An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. (2007) (277)
- Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation (2006) (221)
- Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. (2007) (218)
- Hormone replacement therapy is associated with decreased survival in women with lung cancer. (2006) (192)
- Mining gene expression profiles: expression signatures as cancer phenotypes (2007) (187)
- Genomic signatures to guide the use of chemotherapeutics (2006) (182)
- Linking oncogenic pathways with therapeutic opportunities (2006) (179)
- A genomic strategy to elucidate modules of oncogenic pathway signaling networks. (2009) (111)
- Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. (2008) (111)
- Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. (2007) (108)
- Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma (2009) (94)
- Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors (2008) (93)
- Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. (2009) (90)
- A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities (2008) (90)
- An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer (2008) (89)
- Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma (2003) (84)
- Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. (2008) (81)
- Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential (2009) (80)
- Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors (2006) (78)
- An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2009) (76)
- A genomic approach to identify molecular pathways associated with chemotherapy resistance (2008) (74)
- Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. (2009) (72)
- Role of Her-2/neu Overexpression and Clinical Determinants of Early Mortality in Glioblastoma Multiforme (2003) (68)
- The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design (2010) (68)
- Characterizing the developmental pathways TTF-1, NKX2–8, and PAX9 in lung cancer (2009) (59)
- Genomic strategies for personalized cancer therapy. (2007) (59)
- Age- and sex-specific genomic profiles in non-small cell lung cancer. (2010) (58)
- Anaerobic Spondylodiscitis: Case Series and Systematic Review (2005) (56)
- CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. (2003) (56)
- Gene-expression patterns predict phenotypes of immune-mediated thrombosis. (2006) (55)
- Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. (2002) (49)
- Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. (2009) (48)
- A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia (2009) (47)
- Retraction: Genomic signatures to guide the use of chemotherapeutics (2011) (46)
- Report on EU–USA Workshop: How Systems Biology Can Advance Cancer Research (27 October 2008) (2009) (43)
- HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. (2003) (42)
- Determination of HER-2/Neu Overexpression and Clinical Predictors of Survival in a Cohort of 347 Patients with Primary Malignant Brain Tumors (2004) (42)
- "True" mycotic aneurysm of a renal artery allograft. (1998) (40)
- Fluconazole-Induced Torsade de Pointes (2001) (39)
- Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. (2002) (39)
- Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma (2004) (38)
- Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. (2004) (38)
- Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. (2011) (37)
- Refocusing the War on Cancer: The Critical Role of Personalized Treatment (2010) (35)
- Role of helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance (2002) (34)
- Tyrosine Kinase Inhibitors in Renal Cell Carcinoma (2004) (33)
- Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. (2002) (30)
- Spinal epidural abscess after corticosteroid injections. (2002) (29)
- Breast metastasis from non-small-cell lung carcinoma (2003) (28)
- Predictive value of absent bone marrow iron stores in the clinical diagnosis of iron deficiency anemia. (2003) (27)
- Late Adrenal Metastasis in Operable Non–Small-Cell Lung Carcinoma (2002) (27)
- A Model for Clinical Estimation of Perioperative Hemorrhage (2003) (27)
- Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis. (2002) (26)
- Spinal epidural abscess after tattooing. (1999) (26)
- Utilization of Genomic Signatures to Identify Phenotype-Specific Drugs (2009) (25)
- Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications (2003) (25)
- Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. (2011) (25)
- Prevalence of pesticide exposure in young males (</= 50 years) with adenocarcinoma of the prostate (2003) (24)
- Utilization of genomic signatures to direct use of primary chemotherapy. (2008) (24)
- Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. (2002) (23)
- Predictive value of clinical features at initial presentation in pancreatic adenocarcinoma (2002) (23)
- Uncommon presentations of non-Hodgkin's lymphoma: case 3. Primary renal lymphoma. (2003) (22)
- Toward the individualization of lung cancer therapy (2008) (22)
- Clinical course of lung cancer in patients with chronic kidney disease. (2004) (21)
- Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma (2009) (20)
- Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinoma (2004) (20)
- Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. (2003) (19)
- Pancreatic metastasis and extrahepatic biliary obstruction in squamous cell lung carcinoma (2002) (19)
- Role of HER-2/neu Overexpression and Clinical Features at Presentation as Predictive Factors in Meningiomas (2004) (18)
- Challenging and unusual cases: Case 1. Simultaneous presentation of acute myelogenous leukemia and myocardial infarction. (2003) (17)
- Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. (2006) (17)
- An epidemiological study evaluating the relationship of distance from a tertiary care cancer center to early detection of colorectal carcinoma. (2002) (17)
- Uncommon syndromes and treatment manifestations of malignancy: Case 2. Metastatic non-small-cell lung cancer presenting with leukocytosis. (2003) (17)
- Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. (2001) (16)
- Plasma Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Levels in Acute Myocardial Infarction (2002) (16)
- Epidermal growth factor inhibition in solid tumours (2005) (15)
- Ineffectiveness of the measurement of 'routine' vital signs for adult inpatients with community-acquired pneumonia. (2006) (15)
- HER‐2/neu Overexpression detected by Immunohistochemistry in Soft Tissue Sarcomas (2003) (14)
- Unusual pulmonary lesions: case 3. Pulmonary vein leiomyosarcoma presenting as a left atrial mass. (2002) (14)
- Immunohistochemical determination of HER-2/neu in malignant melanoma. (2003) (13)
- Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. (2003) (13)
- Myeloproliferative syndromes and the associated risk of coronary artery disease. (2003) (13)
- HER-2/neu overexpression in colonic malignancies. (2002) (13)
- Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–7, 2007. (2010) (12)
- Angiosarcoma of the small intestine (2003) (12)
- Chromosomal anomalies in two coexistent myeloproliferative disorders. (2003) (11)
- Immunohistochemical Identification of HER-2/ neu Overexpression and CD117 (c-kit) Expression in Multiple Myeloma (2002) (11)
- HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC) (2005) (10)
- Treatment side effects. Case 3. Fluorouracil-induced exacerbation of systemic lupus erythematosus. (2002) (10)
- Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma. (2003) (10)
- A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC). (2006) (10)
- Risk-awareness of cutaneous malignancies among rural populations (2003) (10)
- Exposure to pesticides increases levels of uPA and uPAR in pre-malignant human prostate cells. (2005) (9)
- B-cell Lymphoma Mimicking Multiple Myeloma (2002) (9)
- Pseudohyperphosphatemia associated with Waldenström's macroglobulinemia (2000) (9)
- Effect of Low-Molecular-Weight Heparin on Potassium Homeostasis (2002) (8)
- Translating genomics into clinical practice: Applications in lung cancer (2009) (7)
- Azathioprine induced hodgkin lymphoma: a case report and review of literature. (2005) (7)
- Retraction. Potti A, Bild A, Dressman HK, Lewis DA, Nevins JR, Ortel TL. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood. 2006;107(4):1391-1396. (2011) (7)
- Retraction for Garman et al., A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities (2011) (7)
- Utility of eosinophil count as predictor of bacteremia. (2004) (7)
- Immunoglobulin and T-cell Receptor Gene-Gene Rearrangement in Pleural Cavity-based T-cell Rich B-cell Lymphoma in an Immunocompetent Patient (2002) (7)
- Unusual tumors involving the head and neck region: case 3. Proptosis due to metastatic prostate cancer. (2001) (7)
- Genomic signatures in non-small-cell lung cancer: Targeting the targeted therapies (2006) (6)
- Adjuvant chemotherapy for early-stage non-small cell lung cancer: the past, the present and the future (2006) (6)
- Regulatable aptamers in medicine: focus on antithrombotic strategies (2004) (6)
- Unusual presentations of thoracic tumors: Case 1. Acute adrenal insufficiency due to metastatic lung cancer. (2001) (5)
- Genomic signatures individualize therapeutic decisions in non-small-cell lung cancer (2007) (5)
- Ineffectiveness of Measuring Routine Vital Signs in Adult Inpatients With Deep Venous Thrombosis (2003) (5)
- Reply to 'Microarrays: retracing steps' (2007) (4)
- Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status (2007) (4)
- Corrigendum: Genomic signatures to guide the use of chemotherapeutics (2008) (4)
- Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy (2004) (4)
- Ecthyma gangrenosum and chronic lymphocytic leukaemia. (2003) (4)
- Effect of hormone replacement therapy on survival in women with lung cancer (2005) (4)
- Group G Streptococcal Endophthalmitis: Case Report and Review of the Literature (2005) (3)
- An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517-525)) (2012) (3)
- Thrombophilia and thrombosis in thrombotic thrombocytopenic purpura. (2005) (3)
- COMPARISON OF RECTAL AND INFRARED EAR TEMPERATURES IN OLDER HOSPITAL INPATIENTS (2000) (3)
- Role of infections in atherogenesis. (2003) (2)
- An indolent B-cell lymphoma with t(2;8)(p12;q24) abnormality and absence of C-MYC amplification and TP53 deletion. A new variant? (2003) (2)
- Unusual abdominal tumors: case 1. Small bowel carcinoid presenting as an acute abdomen. (2003) (2)
- Hyperhomocysteinemia and the risk of thromboembolic phenomenon in patients with chronic renal failure. (2002) (2)
- A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. (2010) (2)
- Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance (2012) (2)
- Unusual presentations of germ cell tumors. Case 3. Nonseminomatous extragonadal germ cell tumor presenting with pulmonary emboli. (2001) (2)
- AT-101 or placebo (P) with docetaxel (D) in second-line NSCLC with gene signature biomarker development. (2009) (2)
- Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587. (2012) (2)
- Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC) (2007) (1)
- A Novel Chemically Induced Fischer F344 Rat Model for Thrombotic Sequelae of Hemolytic Anemias. (2004) (1)
- Correction: Article on Genomic and Molecular Profiling to Predict Response to Temozolomide (2009) (1)
- A clinico-genomic model of performance status in acute myeloid leukemia. (2010) (1)
- Expression profiles associated with disease progression in non-small cell lung cancer. (2010) (1)
- Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. (2009) (1)
- Clinical relevance of insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression. (2010) (1)
- HER-2/neu overexpression and its effect on survival in solid tumors. (2004) (1)
- Peripheral Blood Mononuclear Cell Derived Gene Expression Patterns Identify Clinical Phenotypes and Predict Thrombotic Events in Patients with Immune-Mediated Thrombosis. (2005) (1)
- Anticoagulation patterns and clinical decision‐making following an intermediate ventilation‐perfusion scan in pulmonary thromboembolism (2003) (1)
- Molecular markers of metastases in advanced stage adenocarcinoma of the prostate (2005) (1)
- Corrigenda: Genomic signatures to guide the use of chemotherapeutics (2007) (1)
- Use of co-activation of lung cancer specific developmental pathway genes, TTF-1, NKX2–8, and PAX9, to predict prognosis and guide therapeutic strategies (2008) (1)
- Documenting Biospecimen Conditions in Reports of Studies. Authors' reply (2008) (1)
- Characterizing the clinical relevance of epithelial mesenchymal transition (EMT) in human tumors. (2010) (1)
- A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy (2008) (1)
- Impact of smoking on anatomical distribution and survival in women with lung cancer (2005) (1)
- 487 Gene Expression Profiles for Prognosis Provide a Novel Approach for Selection of Individualized Therapies in Early Stage Colon Carcinoma (2008) (0)
- Gene Expression Patterns Identify Patients with Non-Small Cell Lung Cancer (NSCLC) and Ovarian Cancer Who Are at Increased Risk for Venous Thromboembolism (VTE). (2006) (0)
- Effect of pesticide exposure on HER-2/neu and CD117 overexpression in patients with extensive stage small cell lung carcinoma (ESSCLC). (2004) (0)
- Molecular profiling of smoking-related non-small cell lung cancer (NSCLC) phenotypes. (2010) (0)
- Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples (2008) (0)
- Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2011) (0)
- A genomic approach to identify mechanisms associated with chemotherapy resistance (2007) (0)
- Adjuvant therapy of colon cancer in idiopathic leukopenia (2003) (0)
- UPREGULATED ONCOGENIC PATHWAYS IN PATIENTS EXPOSED TO TOBACCO SMOKE MAY PROVIDE A NOVEL APPROACH TO LUNG CANCER CHEMOPREVENTION (2008) (0)
- A Pathway-Based Approach to Identify Molecular Biomarkers in Cancer (2012) (0)
- Clinical features at presentation, C-kit, and Her2/neu overexpression as prognostic factors in elderly patients with lung carcinoma. (2004) (0)
- microRNA and mRNA expression signatures of Myc and E2F1 oncogenic pathways (2006) (0)
- 54: Development of a Gene Expression Profile for Predicting Gemcitabine Response in Pancreatic Cancer (2009) (0)
- A genomic strategy to combinatorial therapeutics in solid tumors. (2006) (0)
- The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation. (2009) (0)
- Making Mountains out of Molehills: Moving from Single Gene to Pathway Based Models of Colon Cancer Progression (2010) (0)
- Utilization of genomic signatures for chemotherapy response in prospective clinical studies. (2010) (0)
- Gene expression profiles defining molecular subtypes, coupled with signatures of tumor biology and chemotherapy sensitivity provide a novel therapuetic approach to multiple myeloma (2008) (0)
- Retraction: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer (2011) (0)
- Implementing genomically-guided trials in non-small cell lung carcinoma (NSCLC). (2010) (0)
- Findings of research misconduct. (2015) (0)
- Integration of clinico-pathologic variables, mRNA, and microRNA profiles represents an optimal strategy to predict sensitivity to chemotherapeutic agents in breast cancer (2008) (0)
- ACTINOMYCES MEYERI, GANGRENOUS CHOLECYSTITIS, AND INVASIVE CARCINOMA OF THE GALLBLADDER (1999) (0)
- Clinical validation of in vitro drug sensitivity microarray data: Regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01) (2007) (0)
- Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma. (2009) (0)
- Regional Specialization of Endothelial Cells as Revealed by Genomic Analysis (2007) (0)
- A genomic approach to define important and targetable molecular pathways in brain metastasis arising from solid tumors (2008) (0)
- Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia. (2008) (0)
- Gene Expression Profiles for Prognosis in MGUS, Coupled with Signatures of Oncogenic Pathway Deregulation Provide a Novel Approach for Selection of Molecular Targets in Multiple Myeloma. (2007) (0)
- Utilization of Genomic Signatures for Personalized Treatment of Breast Cancer (2020) (0)
- Short communication Chromosomal anomalies in two coexistent myeloproliferative disorders (2003) (0)
- 5BA Clinical validation of in vitro drug sensitivity microarray data: regimen-specific signatures predict pathological complete response to neo-adjuvant chemotherapy for breast cancer in a randomized trial (EORTC 10994/BIG 00-01) (2007) (0)
- Gene expression patterns identify patients with non-small cell lung cancer (NSCLC) who are at increased risk for venous thromboembolism (VTE). (2006) (0)
- Gene expression patterns of oncogenic signaling pathways provide a novel approach to targeted therapeutics in advanced non-small cell lung cancer (NSCLC) (2007) (0)
- Whole Blood Gene Expression Profiles Distinguish Patients with Single Prior Venous Thromboembolism from Patients with Multiple Prior Events. (2007) (0)
- Documenting Biospecimen Conditions in Reports of Studies—Reply (2008) (0)
- T1964 Gene Expression Profiles During Activation of Human Hepatic Stellate Cells Suggest an Epithelial-to-Mesenchymal Transition-Like Process (2010) (0)
- Translational aspects of the common 14q13 amplicon in human lung cancer (2009) (0)
- Use of novel radiosensitizers and radiation-specific miRNAs to modulate radiation response in non-small cell lung adenocarcinoma (NSCLC). (2010) (0)
- Age-specific differences in oncogenic pathway deregulation and chemosensitivity in patients with acute myeloid leukemia: Strategies to maximize response to induction chemotherapy. (2016) (0)
- In reply [6] (2006) (0)
- T1914 Distinguishing Biologically Relevant Phenotypes in Barrett's Esophagus: A Microarray Analysis (2009) (0)
- Development and evaluation of molecular signatures for predicting the efficacy of therapeutics in PI3KCA mutated breast cancer tumors. (2007) (0)
- A genomic signature of chemotherapeutic multidrug resistance provides a rational approach to identify patients for targeted therapy in advanced solid tumors (2007) (0)
- Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Commentary (2006) (0)
- Retraction: Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma (2012) (0)
- Survival and outcome data in patients with adenocarcinoma of the prostate receiving warfarin therapy (2003) (0)
- Effect of pesticide exposure on HER-2/neu and CD117 overexpression in patients with extensive stage small cell lung carcinoma (ESSCLC) (2004) (0)
- A Genomic Strategy To Refine Prognosis and Predict Response to Therapy in Chronic Lymphocytic Leukemia. (2007) (0)
- 218 GENE EXPRESSION PATTERNS IDENTIFY PATIENTS WITH NON-SMALL CELL LUNG CANCER WHO ARE AT INCREASED RISK OF VENOUS THROMBOEMBOLISM. (2007) (0)
- Gene Expression Patterns Identify Novel Biologically Relevant Signaling and Transcriptional Pathways Involved in Terminal Erythroid Differentiation and Polycythemia Vera. (2005) (0)
- Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial. (2009) (0)
- A novel method for drug discovery using genomic phenotypes (2007) (0)
- Integration of mRNA and microRNA profiles as prognostic and predictive markers in lung adenocarcinoma. (2009) (0)
This paper list is powered by the following services:
Other Resources About Anil Potti
What Schools Are Affiliated With Anil Potti?
Anil Potti is affiliated with the following schools:
